Figure 3
From: DCZ19931, a novel multi-targeting kinase inhibitor, inhibits ocular neovascularization
DCZ19931 inhibits ocular neovascularization in vivo. (A,B) C57BL/6J mice received intravitreal injections of 10% DMSO (2 μL, Ctrl), DCZ19931 (2 μL, 1 μg/μL), Ranibizumab (2 μL, 10 mg/mL), Ranibizumab (1 μL, 10 mg/mL) plus DCZ19931 (1 μL, 1 μg/μL) immediately after laser injury. The thickness and areas of neovascular were determined by H & E staining (A, n = 5, scale bar, 50 μm). CNV lesions were visualized by IB4 staining (B, n = 5, scale bar, 100 μm). (C) OIR mouse pups at P12 received intravitreal injections of 10% DMSO (1 μL, Ctrl), DCZ19931 (1 μL, 1 μg/μL), Ranibizumab (1 μL, 10 mg/mL), 1 μL of Ranibizumab (10 mg/mL) plus DCZ19931 (1 μg/μL), respectively. The retinas were harvested on P17 and then stained with GS-IB4 staining to observe retinal vessels. White dashed lines highlighted avascular areas; Yellow area indicated angiogenic regions (n = 5, scale bar, 200 μm). Statistical significance was evaluated by one-way ANOVA followed by Bonferroni post hoc test. *P < 0.05 indicated significant difference between the marked groups.
